Benimetskaya Luba, Stein C A
Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA.
Clin Prostate Cancer. 2002 Jun;1(1):20-30. doi: 10.3816/cgc.2002.n.003.
Currently employed treatment options for patients with advanced and metastatic cancer such as surgery, radiation, hormone therapy, and chemotherapy are limited. In particular, the well known limitations of chemotherapy are at least in part due to a lack of specificity. The activation of dominant oncogenes and inactivation of tumor suppressor genes may represent novel targets for cancer therapy. Antisense therapy has been widely used to specifically and selectively inhibit the expression of selected genes at the messenger RNA level. Combinations of antisense oligonucleotides with chemotherapeutic agents may offer important advantages in cancer treatment. Several antisense drugs, especially oblimersen (G3139), have shown interesting results in experiments in animals, and have entered clinical trials. However, control oligonucleotides must be carefully chosen to separate antisense effects from the many potential nonspecific effects of oligonucleotides. This review summarizes the advantages and limitations of antisense therapy and its use in the treatment of androgen-independent prostate cancer.
目前用于晚期和转移性癌症患者的治疗选择，如手术、放疗、激素疗法和化疗，都存在局限性。特别是，化疗众所周知的局限性至少部分是由于缺乏特异性。主导癌基因的激活和肿瘤抑制基因的失活可能代表癌症治疗的新靶点。反义疗法已被广泛用于在信使RNA水平特异性和选择性地抑制选定基因的表达。反义寡核苷酸与化疗药物的联合使用可能在癌症治疗中具有重要优势。几种反义药物，尤其是奥曲肽（G3139），在动物实验中已显示出有趣的结果，并已进入临床试验。然而，必须仔细选择对照寡核苷酸，以将反义效应与寡核苷酸许多潜在的非特异性效应区分开来。本综述总结了反义疗法的优缺点及其在治疗雄激素非依赖性前列腺癌中的应用。
